Technology
Health
Pharmaceutical

Collegium Pharmaceutical

$17.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.06%) Today
+$0.01 (0.06%) Today

Why Robinhood?

You can buy or sell COLL and other stocks, options, ETFs, and crypto commission-free!

About

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. Read More The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Employees
266
Headquarters
Stoughton, Massachusetts
Founded
2003
Market Cap
576.83M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
468.34K
High Today
$17.35
Low Today
$17.35
Open Price
$17.35
Volume
7.04K
52 Week High
$28.91
52 Week Low
$13.10

Collections

Technology
Health
Pharmaceutical
2015 IPO
US
North America

News

MarketBeatMar 8

Stock Price, News, & Analysis for Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also ...

6
Seeking AlphaFeb 27

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2018 Results - Earnings Call Transcript

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2018 Results Conference Call February 27, 2019 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joe Ciaffoni - CEO Paul Brannelly - CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants Serge Belanger - Needham & Company David Amsellem - Piper Jaffray Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Ed Arce - H.C. Wainwright & Co. Kevin Kedra - G. Research Operator Good day, ladies and gentlemen, and welcome t...

24
Simply Wall StFeb 22

Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL) A Financially Sound Company?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a small-cap stock with a market capitalization of US$498m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. Why is it important? Companies operating in the Pharmaceuticals industry...

98

Earnings

-$0.83
-$0.60
-$0.38
-$0.15
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.